Avalon GloboCare (ALBT) said Tuesday it received a notice of allowance from the China National Intellectual Property Administration for its patent application covering a technology designed to "enhance" the expansion, manufacturing, survival, and efficacy of chimeric antigen receptor, or CAR-T and CAR-natural killer cells.
The company said it co-developed the patent with Hong Kong-based Arbele.
Avalon GloboCare shares were up 7.3% in recent trading.
Price: 3.96, Change: +0.27, Percent Change: +7.32
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。